• Add this page to "Favorite pages"
  • Print the text(Open link in a new browser window)
Here begins the text.

PMDA’s Efforts to Combat COVID-19

PMDA’s Efforts to Combat COVID-19

Approved Medical Products for COVID-19

 The following products were approved for COVID-19 by the Ministry of Health, Labour and Welfare after March 2020 with prior scientific review by the PMDA.
 For information of products under review by the PMDA or development by sponsors, please contact sponsors or developers of the product.

Drugs

Active Ingredient Brand Name Applicant Company Approval Date
Remdesivir VEKLURY for Intravenous Injection Gilead Sciences K.K. May 7, 2020
(approved based on article 14-3 of the PMD Act)

 

Medical Devices

Japanese
Medical Device
Nomenclature
(JMDN)
Brand Name Applicant Company Approval Date
Ventilator for general purpose NKV-550 Series Ventilator System NIHON KOHDEN CORPORATION April 24, 2020
Bi-level positive airway pressure unit Philips Respironics E30 ventilator Philips Japan, Ltd. May 1, 2020
Adult ventilator Philips Trilogy Evo Series Philips Japan, Ltd. May 12, 2020
Software for diagnostic X-ray imaging system workstation Pulmonary image analyses program "InferRead CT Pneumonia" CES Descartes Co., Ltd. June 3, 2020
Adult ventilator Puritan Bennett 560 Covidien Japan, Inc. June 12, 2020
Adult ventilator ACOMA Ventilator ART-21EX ACOMA Medical Industry Co., Ltd June 19, 2020
Heparin-coated aortic cannula NSH heparin cannulae SENKO MEDICAL INSTRUMENT Mfg. CO., LTD. June 25, 2020
Software for diagnostic X-ray imaging system workstation COVID-19 Pneumonia Image Analysis Program Ali-M3 MIC Medical Corp June 29, 2020
Heart-lung bypass system Heart Lung Machine S5 LivaNova Deutschland GmbH
(designated MAH*1: LivaNova (Japan) K.K.)
July 13, 2020
Multiparameter monitor with critical parameters IntelliVue Patient Monitors MX750/850 Philips Japan, Ltd. July 31, 2020

*1 designated holder of marketing authorization for foreign-manufactured products

In Vitro Diagnostics

Japanese
Medical Device
Nomenclature
(JMDN)
Brand Name Applicant Company Approval Date Other Information
SARS-CoV-2 nucleic acid kit 2019-nCoV Fluorescence Detection Real-time RT-PCR Kitv Sysmex Corporation March 27, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 nucleic acid kit Loopamp Novel Coronavirus 2019 (SARS-CoV-2) Detection Kit Eiken Chemical Co., Ltd. March 31, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 nucleic acid kit cobas SARS-CoV-2 Roche Diagnostics K.K. April 7, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 nucleic acid kit TaqPath Real Time PCR Reagent Kit for SARS-CoV-2 Life Technologies Japan Ltd. April 20, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 nucleic acid kit Xpert Xpress SARS-CoV-2 ‘Cepheid’ Beckman Coulter, Inc. May 8, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 antigen kit ESPLINE SARS-CoV-2 Fujirebio Inc. May 13, 2020 Review Summary
SARS-CoV-2 nucleic acid kit MEBRIGHT SARS-CoV-2 Kit Medical & Biological Laboratories Co., Ltd. May 21, 2020 *2 partial change was approved on June 2.
SARS-CoV-2 nucleic acid kit / Virus Nucleic Acid Isolation Kit / Bacterial Nucleic Acid Isolation Kit FilmArray Respiratory Panel 2.1 bioMérieux Japan Ltd. June 2, 2020  
SARS-CoV-2 antigen kit Lumipulse SARS-CoV-2 Ag Fujirebio Inc. June 19, 2020  
SARS-CoV-2 nucleic acid kit GENECUBE SARS-CoV-2 TOYOBO CO., LTD. July 2, 2020  
SARS-CoV-2 nucleic acid kit TRCReady SARS-CoV-2 Tosoh Corporation July 31, 2020  
SARS-CoV-2 antigen kit QuickNavi-COVID19 Ag Denka Co., Ltd. August 11,
2020
 

*2 Due to the addition of specimen types to COVID-19 Manual by the National Institute of Infectious Diseases, partial change was approved on June 2 to add saliva as a specimen type to those already approved, e.g, specimen obtained from bronchoalveolar lavage and nasopharyngeal swabs.

International Cooperation

 The PMDA has been discussing the regulatory considerations for anticipated medical products for COVID-19 under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). The ICMRA is a voluntary, executive-level, strategic coordinating, advocacy and leadership entity of regulatory authorities that work together.
 

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000047465
0
PMDA’s Efforts to Combat COVID-19
/english/about-pmda/0002.html
en